The repurchase is part of a commitment announced by the company in July 2016 to return $300 million to shareholders by the end of 2017.
Qiagen plans to return about $250 million to shareholders through a program that combines a direct capital repayment with a reverse stock split.
Revenues rose thank to an increase in the company's human health business, which offset a decline in its environmental health segment.
As of the end of its fiscal third quarter of 2016, Myriad had repurchased more than $1.1 billion of stock since the inception of the buyback program in 2010.
Under the repurchase plan, Thermo Fisher is cleared to buy $1 billion of its common stock in both the open market and through negotiated transactions.
The program will run for two years, and Bruker said that it will repurchase its common stock from time to time in amounts and at prices that it deems appropriate.
The firm also completed the repurchase of $96 million in common shares under a previous share repurchase program.
The program will begin in November or when the existing share repurchase program is completed.
The buyback program will target the repurchase of less than 1 percent of shares and is not set for a specific number of shares or dollar amount.
This is the third tranche of Qiagen's share repurchase program. In the first two tranches, Qiagen repurchased about $50 million of its shares.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.